Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022
October 31, 2022 16:05 ET
|
Intercept Pharmaceuticals, Inc.
Data from Phase 3 REGENERATE study supporting positive benefit-risk profile of obeticholic acid (OCA) in liver fibrosis due to NASH to be featured in late-breaker podium presentation Analysis...
Intercept to Announce Third Quarter 2022 Financial Results on November 1, 2022
October 25, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Pharmaceuticals to Participate in H.C. Wainwright’s 6th Annual NASH Investor Conference on October 17, 2022
October 12, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint
September 30, 2022 07:55 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel...
Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning
September 21, 2022 07:30 ET
|
Intercept Pharmaceuticals, Inc.
Outstanding debt reduced by 54% or $388.9 million and annual cash interest expense reduced by 58% or $13.6 million Company well-positioned to drive continued growth in PBC, progress NASH program,...
Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology
September 20, 2022 12:45 ET
|
Intercept Pharmaceuticals, Inc.
Combined clinical trial and real-world data with six years of follow-up provides important evidence of efficacy Analysis compares findings from the Phase 3 POISE trial and open-label extension to...
Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
September 07, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel...
Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Citi 17th Annual BioPharma Conference September 8, 2022
August 29, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Pharmaceuticals Announces Repurchase of Convertible Notes
August 19, 2022 07:30 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of...
Intercept Pharmaceuticals to Participate in B. Riley’s PBC Symposium on August 24, 2022
August 18, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...